期刊
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 56, 期 5, 页码 968-974出版社
OXFORD UNIV PRESS
DOI: 10.1093/jac/dki319
关键词
tuberculosis; drugs; in vivo efficacy; cytotoxicity
资金
- NIAID NIH HHS [1UC1 AI-049514-01] Funding Source: Medline
Objectives: The aim of this study was to identify a candidate drug for clinical development from a previously synthesized combinatorial library based on the 1,2-ethylenediamine structure of ethambutol. Methods: Sixty-nine of the most potent hits against Mycobacterium tuberculosis from the original studies were subjected to a sequential set of tests in vitro and in vivo-determination of MIC for M. tuberculosis H37Rv, cytotoxicity, intracellular antimycobacterial activity, permeability evaluation and in vivo efficacy testing. Results: Twenty-seven compounds with MICs of <= 15.6 mu M were tested on Vero cells to determine in vitro cytotoxicity (IC50) and to establish a selectivity index (SI) (SI = IC50/MIC). Ten compounds with acceptable SI were tested for activity against intracellular bacteria-all were equivalent (within 1%) or superior to ethambutol and several demonstrated cidal activity. Five of the most potent compounds were tested for in vivo efficacy in a murine model of chronic tuberculosis infection. Conclusion: Compound SQ109 with an MIC of 0.7-1.56 mu M (H37Rv, Erdman and drug-resistant strains of M. tuberculosis), an SI of 16.7 and 99% inhibition activity against intracellular bacteria, demonstrated potency in vivo and limited toxicity in vitro and in vivo, and was selected for further development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据